Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: Long-term results

Acta Ophthalmologica

Volumn 89, Issue 2, 2011, Pages 179-184

  Julián, Karina ^a   Terrada, Céline ^a   Fardeau, Christine ^a   Cassoux, Nathalie ^a   Français, Catherine ^b   LeHoang, Phuc ^a   Bodaghi, Bahram ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre Ophtalmologique de l'Odeon   (France)

Author keywords

Intravitreal; Neovascularization; Treatment; Uveitis

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; BEVACIZUMAB; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AMPIGINOUS CHOROIDITIS; ARTICLE; CLINICAL ARTICLE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MALE; MEDICAL RECORD REVIEW; MULTIFOCAL CHOROIDITIS; OCULAR TUBERCULOSIS; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION; SYMPATHETIC OPHTHALMIA; SYMPATHETIC OPTHLALMIA; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 79952223957     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02046.x     Document Type: Article

References (30)

1. Adan A, Mateo C, Navarro R, Bitrian E & Casaroli-Marano RP (2007): Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27: 1180-1186. (Pubitemid 350211522)
2. Aiello LP, Brucker AJ, Chang S et al. (2004): Evolving guidelines for intravitreous injections. Retina 24: S3-S19. (Pubitemid 39391785)
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP & Ianchulev T (2009): Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-65.e5.
4. Chan WM, Lai TY, Liu DT & Lam DS (2007): Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114: 2190-2196.
5. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J & Klesert TR (2007): Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125: 1460-1469. (Pubitemid 350106676)
6. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr & Slakter JS (2008): Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 126: 941-945. (Pubitemid 352008374)
7. Dees C, Arnold JJ, Forrester JV & Dick AD (1998): Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol 116: 1456-1461. (Pubitemid 28520664)
8. Deschenes J, Murray PI, Rao NA & Nussenblatt RB (2008): International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm 16: 1-2. (Pubitemid 351480322)
9. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P & Murray PI (2004): Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88: 1159-1162. (Pubitemid 39141376)
10. Fine SL, Wood WJ, Isernhagen RD et al. (1993): Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: results of a pilot randomized clinical trial. Arch Ophthalmol 111: 19-20. (Pubitemid 23022874)
11. Fine HF, Baffi J, Reed GF, Csaky KG & Nussenblatt RB (2001): Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132: 794-796. (Pubitemid 33031303)
12. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD & Gregor ZJ (1998): The use of corticosteroids for choroidal neovascularisation in young patients. Eye 12(Pt 2): 266-272. (Pubitemid 28263868)
13. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M & Guyer DR (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816. (Pubitemid 40051904)
14. Grossniklaus HE, Ling JX, Wallace TM et al. (2002): Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8: 119-126. (Pubitemid 36153599)
15. Hawkins BS, Miskala PH, Bass EB, Bressler NM, Childs AL, Mangione CM & Marsh MJ (2004): Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial: SST Report No. 10. Arch Ophthalmol 122: 1616-1628. (Pubitemid 39473406)
16. Heier JS, Antoszyk AN, Pavan PR et al. (2006): Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I?II multicenter, controlled, multidose study. Ophthalmology 113: 633.e1-633.e4.
17. Hogan A, Behan U & Kilmartin DJ (2005): Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 89: 1109-1111. (Pubitemid 41224455)
18. Kurup S, Lew J, Byrnes G, Yeh S, Nussenblatt R & Levy-Clarke G (2009): Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol 87: 349-352.
19. Kwak N, Okamoto N, Wood JM & Campochiaro PA (2000): VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41: 3158-3164.
20. Mansour AM, Mackensen F, Arevalo JF et al. (2008): Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 146: 410-416.
21. Neri P, Manoni M, Fortuna C, Lettieri M, Mariotti C & Giovannini A (2009a): Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunesuppressants: interventional case series. Int Ophthalmol PMID : 19727566.
22. Neri P, Salvolini S, Mariotti C, Mercanti L, Celani S & Giovannini A (2009b): Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br J Ophthalmol 93: 155-158.
23. Parodi MB, Di Crecchio L, Lanzetta P, Polito A, Bandello F & Ravalico G (2004): Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 138: 263-269. (Pubitemid 39037431)
24. Parodi MB, Iacono P, Spasse S & Ravalico G (2006): Photodynamic therapy for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 141: 123-128. (Pubitemid 43016181)
25. Perentes Y, Chan CC, Bovey E, Uffer S & Herbort CP (2002): Massive vascular endothelium growth factor (VEGF) expression in Eales' disease. Klin Monatsbl Augenheilkd 219: 311-314. (Pubitemid 34625244)
26. Rosenfeld PJ, Rich RM & Lalwani GA (2006): Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19: 361-372. (Pubitemid 44279358)
27. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A & Naumann GO (2003): Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium- derived factor. Invest Ophthalmol Vis Sci 44: 4473-4480. (Pubitemid 37186285)
28. Spaide RF (2006): Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141: 149-156.
29. Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B & Lehoang P (2008): Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 246: 1685-1692.
30. Tsutsumi-Miyahara C, Sonoda KH, Egashira K et al. (2004): The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation. Br J Ophthalmol 88: 1217-1222. (Pubitemid 39141387)